Background
Alzheimer's disease is a progressive neurodegenerative disorder characterized by intra-cellular abnormally phosphorylated tau protein and extra-cellular beta amyloid plaques. It has been suggested that inflammation may be a key player in the pathophysiology of AD as evidenced by epidemiological studies which have revealed that the long term use of non-steroidal anti-inflammatory drugs reduces the risk of developing AD [
1‐
3]. Transgenic mouse models of Alzheimer's disease that over-express β-amyloid (Aβ) exhibit significant cerebrovascular inflammation and microgliosis around areas of plaque deposition [
4‐
7]. Chronic administration of ibuprofen can reduce plaque pathology and brain Aβ levels in these animal models of AD [
8,
9].
There are numerous reports of increased levels of cytokines in the brains of Alzheimer's disease patients, and in transgenic mouse models of Alzheimer's disease [
10‐
12]. However, all these reports have focused on a small number of cytokines within the same sample. It is not clear which cytokines are key in promoting and maintaining the inflammatory environment in the AD brain. Furthermore, it is unclear which Aβ species (1–40, 1–42, soluble or insoluble) are most closely related to cytokine levels. Multiplex technology enables the simultaneous quantification of many cytokines within a single sample.
By examining different mouse models of AD using multiplex technology, it is possible to more clearly characterize the particular cytokines which maintain the inflammatory environment and to relate them to particular forms of Aβ (1–40, 1–42, soluble or insoluble).
There is considerable debate over which length of Aβ and which conformations are most potently toxic. Recently, specific oligomeric forms have been shown to be most toxic to neurons. These soluble species of Aβ differ from the higher-molecular-weight aggregated insoluble forms that are found precipitated in the AD patient and mouse brain. This study sought to determine whether soluble or insoluble Aβ fractions were most closely related to cytokine levels.
Discussion
Levels of both peripheral and local CNS cytokines are elevated in AD patients, indicating that there is cellular activation occurring in response to inflammatory stimuli [
15‐
20]. However, there is still considerable debate over exactly what is triggering this inflammation. Studies using mouse models of AD have shown that ibuprofen is effective in reducing plaque pathology and also in improving behavioral deficits characteristic of these transgenic models [
8,
21]. The transgenic mouse models used to study AD exhibit some of the pathological features seen in the AD patient brain and show an increased production of inflammatory markers such as COX-2, PGE
2 and also increased levels of the pro-inflammatory cytokines IFN-γ and IL-12, TNF-α, IL-1α, IL-1β and IL-6 [
12,
22]. Pathological analysis of tissue from AD patients and from mouse models of AD shows that there is extensive astrocytic and microglial activation around areas of Aβ plaque deposition [
6,
7]. In addition, the chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with a reduced risk of developing AD [
23,
24], suggesting that inflammation is an important contributor to the pathophysiology of AD.
One aim of this study was to create a cytokine expression profile for organotypic brain slice cultures from transgenic mouse models of Alzheimer's disease, and to further relate this increase to the level of Aβ present in the brain. Another purpose of our study was to determine whether inflammatory events may be correlated with the accumulation of particular forms of Aβ; either soluble or insoluble.
In the current study, we used the organotypic brain slice culture model to assess multiple cytokine production in the culture medium surrounding brain slices from transgenic mice that are engineered to over-produce Aβ. Cytokine production from 15-month-old control, PS1, TgAPPsw and PS1/APPsw mouse brain slices was assessed using the Bioplex cytokine multi-array system. Cytokine levels were not significantly elevated in PS1 brain slices compared to control slices, indicating that the PS1 (M146L) mutation does not have a significant impact on cytokine production. No significant change in the production of IL-4 and IL-10 was observed in the brains of these transgenic mice compared to their respective controls, indicating the absence of an anti-inflammatory response. All of the cytokines that were increased in the TgAPPsw brain slices (IL-1α, TNF-α, GM-CSF and IL-6) were further increased in the PS1/APP brain slices. This suggests that the presence of these inflammatory molecules is related to the amount of β-amyloid protein present, in agreement with a pro-inflammatory effect of Aβ [
25‐
29]. A recent report has also shown increases in IL-1β, IL-6 and TNFα in-vivo after intra-cerebral administration of fibrillar Aβ into rat brain [
30].
In order to further understand the correlation between the amount of Aβ and cytokine levels in the brains of transgenic mice, levels of both soluble and insoluble (formic acid-extracted) Aβ1–40 and 1–42 were quantified in the same slices from which cytokine production was measured, allowing a direct correlation of Aβ-cytokine levels.
Levels of soluble and insoluble Aβ1–40 correlated well with each other, and the same was observed for Aβ1–42. As expected, quantification of Aβ levels generally revealed significantly higher amyloid levels in the PS1/APPsw mouse brain slices compared to TgAPPsw (for soluble Aβ, approximately 15 fold more Aβ1–40, and 20 fold more 1–42) but there was considerable slice-to-slice variation in soluble and insoluble Aβ levels within and between genotypes. The TgAPPsw and PS1/APPsw mice express equal levels of the APPsw molecule, but the PS1/APPsw model produces greater levels of Aβ and develops plaques at an earlier age (10 weeks) [
31‐
33]. This increased deposition of Aβ in the PS1/APPsw mouse is due to a PS1 mutation, resulting in increased production of Aβ1–42 [
34‐
36].
The Aβ data in the current report found a significant range of values for soluble:insoluble Aβ ratios between brain slices. This broad spread of values allowed correlation with equally wide ranges of cytokine production. This approach of examining Aβ-cytokine correlations within the same slices in the same aged animals eliminated the confounding factor of age related changes in cytokine production. Both Aβ1–40 and 1–42 correlated closely with all the cytokines that changed in the brain slices, but the correlation was particularly striking with IL-12p40. IL-12 is a hetero-dimeric cytokine which can comprise two subunits; IL-12p40 and IL-12p35. It is produced mainly by monocytes and macrophages and is a crucial factor in directing the T-cell response to infection, by inducing a Th1-type cytokine response. Our data agrees with that of previous reports showing that IL-12p40 is strongly up-regulated in-vitro (in response to an inflammatory stimulus) and in-vivo in the cerebral cortex of TgAPPsw mice [
12,
37,
38].
IL-1, which was increased in the transgenic brain slices, is a major immune-response molecule functioning in the periphery and brain. The family comprises three related proteins (IL-1α, IL-1β and IL-1 receptor antagonist (IL-1ra)). IL-1α and IL-1β are two different isoforms of IL-1 that have similar affinities for their receptor IL-1R, and therefore have similar activities. Both are capable of inducing inflammatory cascades in-vivo and in-vitro, and it has been shown that they are capable of up-regulating expression of astrocyte-derived S100B and APP [
39,
40]. It has been shown that IL-1β can promote β-secretase cleavage of APP in human astrocytes and thereby increase production of Aβ1–40 and 1–42 [
41,
42]. It is also known that accumulation of plaques and the formation of neurofibrillary tangles are correlated with increased IL-1 levels in the AD brain [
43‐
45]. Certain polymorphisms of IL-1A (the gene for IL-1α) are associated with late onset AD, although there is controversy as to whether all IL-1 gene polymorphisms represent risk factors for AD [
46‐
50]. Microglia, in particular, have been shown to locally up regulate IL-1α at both the protein and mRNA level when inflamed, a situation that occurs in chronic disease states such as AD [
51]. Both IL-1α and IL-1β can enhance the translation of APP mRNA in human astrocytes [
52]; an up-regulation of IL-1α/β production in-vivo could therefore increase Aβ production, and an inflammatory cycle with increased Aβ levels may further increase IL-1α/β production.
The Aβ 1–42:40 ratio is also of considerable interest in relation to cytokine levels and although there are currently no studies correlating Aβ 1–42:40 ratio with cytokine levels in-vivo, certain reports have suggested that cytokines can modulate Aβ production [
53‐
55]. PS1 mutations are known to cause a shift in the production of Aβ species, favoring the production of Aβ1–42 over 1–40 and causing an increase in the Aβ1–42:40 ratio [
56]. Since TNF-α correlated better with the level of Aβ1–42 than with that of Aβ 1–40, and correlated particularly well with the Aβ1–42:40 ratio in our study, TNF-α levels may be partly determined by this ratio. Higher levels of Aβ1–42 can promote the formation of toxic oligomers [
57‐
59], and it therefore seems possible that the increased level of Aβ oligomers in PS1/APP mice (compared to APPsw) and the level of oligomeric forms present in the brains of our transgenic mice may be related to the amount of TNF-α being produced.
It is important to consider the nature of the exact form of Aβ that may be most responsible for the inflammatory events seen in AD brains. Aβ can exist in various forms (monomeric, dimeric, oligomeric and fibrillar), but it is not yet clear which of these forms are most potent in inducing inflammatory cellular responses [
57,
60,
61]. This is of interest because the oligomeric forms of Aβ which are thought to be the most toxic are produced more readily by Aβ1–42 (for review see [
62]). Future studies will assess the relative proportions of monomers/dimers, oligomers or fibrils occurring in these mice brains and their relationship with the cytokine increases observed.
Competing interests
The author(s) declare that they have no competing interests.
Authors' contributions
NP carried out the in-vitro brain slice assays, processed brain tissues, performed the Bio-plex assay, ELISAs and drafted the manuscript. DP conceived the design of the study, carried out Bio-plex assays, performed statistical analyses and aided in manuscript preparation. VM analyzed data and constructed dendrograms. AQ aided in ELISA and Bio-plex assays and collected mouse brain tissues. FC oversees management of the mouse colonies. MM aided in manuscript preparation and gave critical analysis of the manuscript.